colonoscope News
-
Lumendi Reports First Incisionless Appendectomy Using Double-Balloon Endolumenal Interventional Platform
Patient reported no post-procedure pain and resumed regular activity day after procedure Connecticut-based medical device innovator Lumendi, LLC reports the first endoscopic appendectomy using its DiLumenTM Endolumenal Interventional Platform (EIP). A patient underwent the purely endoscopic endolumenal appendectomy to remove a lesion previously identified at the appendiceal orifice. ...
By Lumendi Ltd.
-
EM Imaging obtains global licence for optical agent that detects cancer early
Edinburgh Molecular Imaging Ltd. (EM Imaging) has signed an exclusive global license for a novel optical imaging agent that could improve the detection of early-stage colorectal (bowel) cancer. EM Imaging, a company which develops and commercialises novel optical imaging agents, recently signed the licensing agreement with GE Healthcare Ltd. and Dyax Inc. EM Imaging will now complete the ...
-
EZ Glide Pushes Lumendi to New Quarter-Over-Quarter Sales Record
EZ Glide, the most recent enhancement to Lumendi’s DiLumen Endoluminal Interventional Platform (EIP), has achieved significant quarter-over-quarter product sales since its market introduction in Q4 2020, and is on track to double the sales revenue from the prior year. Launched in December 2020, EZ Glide is helping to significantly increase the platform’s useability in GI ...
By Lumendi Ltd.
-
Guardant Health Announces Shield™ Blood Test Available in US to Detect Early Signs of Colorectal Cancer in Average-Risk Adults
Highly sensitive Shield test offers convenient screening method that can be completed with simple blood draw, helping overcome barriers to compliance Test demonstrated sensitivity of 91% in colorectal cancer and 20% in advanced adenoma detection with specificity of 92% in validation studies PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you